证券代码：600200 证券简称：江苏吴中 编号：临2024-031 江苏吴中医药发展股份有限公司 关于 2024 年度为所属全资子公司提供担保的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示: 被担保人名称：江苏吴中医药集团有限公司、江苏吴中医药集团有限公司苏 州制药厂、江苏吴中医药销售有限公司、江苏吴中海利国际贸易有限公司、江苏 吴中美学生物科技有限公司、江苏吴中进出口有限公司、中吴贸易发展（杭州） 有限公司。 本次担保金额及已实际为其提供担保余额：2024 年度江苏吴中医药发展股 份有限公司（以下简称"公司"、"本公司"或"上市公司"）为所属全资子公司 提供担保的最高限额为 319,000 万元。其中为资产负债率 70%以下的被担保对象 提供担保的额度为 204,000 万元；为资产负债率 70%以上的被担保对象提供担保 的额度为 115,000 万元。在全年预计担保总额范围内，被担保对象的担保额度可 以在同类担保对象间调剂使用。截至本公告披露日，公司及所属子公司实际担保 总额为 144,960.04 万元 ...

一、募集资金基本情况 证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-030 江苏吴中医药发展股份有限公司关于非公开发行 募集资金 2023 年度存放与实际使用情况的专项报告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及相关 格式指引的要求，现将本公司非公开发行募集资金 2023 年度存放与实际使用情 况专项报告如下： (一)实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准江苏吴中实业股份有限公司非公开发 行股票的批复》(证监许可[2015]2084号)核准，本公司获准非公开发行不超过 4,538万股新股(以下简称"本次发行")。本次发行实际发行数量为41,046,070 股，发行对象为6名，发行价格为12.52元/股，募集资金总额513,896,796.40元(含 发行费用)。扣除发行费用合计人民币11,519,544.24元后，本次募集资金净额为 人民币502,377,252.16元，上述募集资金已于2015年9月29日划 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-035 江苏吴中医药发展股份有限公司关于拟 变更公司注册资本及修订《公司章程》的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 二、《公司章程》修改情况 根据公司注册资本变更情况公司拟对《公司章程》的相应条款进行修改。具 体修改内容见下表： | 序号 | 原条款为 | 拟修改为 | | --- | --- | --- | | 1 | 第六条 公司注册资本为人民币 | 第六条 公司注册资本为人民币 | | | 712,285,832 元。 | 712,200,832 元。 | | | 第十九条 公司股份总数为 712,285,832 | 第十九条 公司股份总数为 712,200,832 | | 2 | 股 ， 公 司 的 股 本 结 构 为 ： 普 通 股 | 股，公司的股本结构为：普通股 712,200,832 | | | 712,285,832 股。 | 股。 | | | 第四十条 股东大会是公司的权力机构，依 | 第四十条 股东大会是公司的权力机构，依法 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-036 江苏吴中医药发展股份有限公司 关于提请股东大会授权董事会办理小额快速融资相关 事宜的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开了第十一届董事会第一次会议，审议通过了《江苏吴中医药发展股份有限 公司关于提请股东大会授权董事会办理小额快速融资相关事宜的议案》，本议案 尚需提交 2023 年年度股东大会审议。具体情况如下： 根据中国证券监督管理委员会《上市公司证券发行注册管理办法》（以下简 称"《注册管理办法》"）等相关规定，公司董事会拟提请股东大会授权董事会 向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的 股票，授权期限为自公司 2023 年年度股东大会审议通过之日起至公司 2024 年年 度股东大会召开之日止。本次授权事宜包括以下内容： 1、确认公司是否符合以简易程序向特定对象发行股票（以下简称"小额快 速融资"）的条件 授权董事会 ...

关于江苏吴中医药发展股份有限公司 2023 年度募集资金存放与使用情况 鉴证报告 中兴财光华审专字（2024）第 318031 号 目 · Zhongxingcai Guanghua Certified Public Accountants LLP ADD:A-24E. Vanton Financial Center No.2 Fuchengmenwal Avenue, Xicheng District, Beijing, China 关于江苏吴中医药发展股份有限公司 2023年度募集资金存放与使用情况 鉴证报告 中兴财光华审专字(2024)第 318031 号 江苏吴中医药发展股份有限公司全体股东: 关于江苏吴中医药发展股份有限公司 2023 年度募集 资金存放与使用情况鉴证报告 2023 年度募集资金存放与使用情况专项报告 1-8 我们审核了后附的江苏吴中医药发展股份股份有限公司(以下简称"江苏吴 中公司")《2023年度募集资金存放与使用情况的专项报告》(以下简称"募集 资金专项报告")。 一、董事会的责任 江苏吴中公司董事会的责任是按照《上市公司监管指引第2号 -- 上市公司 募集资金管理和使用的监管 ...

关于江苏吴中医药发展股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 1、 专项审计报告 关于江苏吴中医药发展股份有限公司 2023年度非经营性 资金占用及其他关联资金往来情况的专项说明 中兴财光华审专字(2024)第318032 号 江苏吴中医药发展股份有限公司全体股东: 目 录 2、 附表 委托单位：江苏吴中医药发展股份有限公司 审计单位：中兴财光华会计师事务所（特殊普通合伙） 联系电话：010-52805600 Zhongxingcai Guanghua Certified Public Accountants LLP ADD:A-24F Vanton Financial Center No.2 Eucher e, Xichena District, Beijing, Ch -AX-010_52805601 中国注册会计师: 中国注册会计师: 2024 年 4 月 23 日 关于江苏吴中医药发展股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况表 单位：万元 我们接受江苏吴中医药发展股份有限公司(以下简称"江苏吴中公司")委 托,根据中国注册会计师执业准则审计了 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-033 江苏吴中医药发展股份有限公司 关于第一期员工持股计划第二个锁定期届满暨解锁 条件成就的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开第十一届董事会第一次会议和第十一届监事会第一次会议，审议通过了 《关于第一期员工持股计划第二个锁定期届满暨解锁条件成就的议案》，具体情 况如下： 一、本员工持股计划的实施进展 6、2024 年 4 月 23 日，公司召开第十一届董事会第一次会议及第十一届监 事会第一次会议，审议通过《公司关于第一期员工持股计划第二个锁定期届满暨 解锁条件成就的议案》。 1、2021 年 12 月 16 日，公司召开了第十届董事会 2021 年第四次临时会议 （通讯表决），审议通过了《关于<江苏吴中医药发展股份有限公司第一期员工 持股计划（草案）>及其摘要的议案》《关于<江苏吴中医药发展股份有限公司第 一期员工持股计划管理办法>的议案》《关于提请股东大会授 ...

浙江天册律师事务所 关于 江苏吴中医药发展股份有限公司 2021 年限制性股票激励计划部分解除限售 及回购注销部分限制性股票相关事项的 法律意见书 〒 浙江天册律师事务所 浙江杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话: 0571 8790 1111 传真: 0571 8790 1500 http://www.tclawfirm.com 天册律师事务所 法律意见书 浙江天册律师事务所(以下称"本所")接受江苏吴中医药发展股份有限 公司(以下称"江苏吴中"或"公司")的委托,担任公司本次限制性股票激励 计划(下称"本次股权激励计划""本激励计划"或"本计划")的专项法律顾 问。 本所根据《中华人民共和国证券法》(下称"《证券法》")《中华人民 共和国公司法》（下称"《公司法》"）、中国证券监督管理委员会（下称"中 国证监会"）发布的《上市公司股权激励管理办法》（下称"《管理办法》"） 等有关法律、法规和规范性文件以及《江苏吴中医药发展股份有限公司章程》(下 称"《公司章程》")的规定,按照律师行业公认的业务标准、道德规范和勤勉 尽责精神,对江苏吴中提供的有关文件进行了核查和验证,现就 ...

Financial Performance - In 2023, the company reported a consolidated net profit of -71,945,211.87 CNY, with the parent company's net profit at -75,861,942.60 CNY[5]. - The parent company's undistributed profits at the beginning of the year were -834,918,068.55 CNY, ending the year with -910,780,011.15 CNY, indicating a decrease in retained earnings[5]. - The company will not distribute profits or increase capital reserves through stock conversion for the year 2023[5]. - The company's operating revenue for 2023 reached approximately ¥2.24 billion, representing a year-over-year increase of 10.55% compared to ¥2.03 billion in 2022[25]. - The net profit attributable to shareholders was a loss of approximately ¥71.95 million, an improvement from a loss of ¥76.27 million in 2022[25]. - The net cash flow from operating activities decreased significantly to approximately -¥203.68 million, down from ¥56.27 million in the previous year, marking a decline of 461.94%[25]. - The total assets increased by 10.67% to approximately ¥4.33 billion at the end of 2023, compared to ¥3.91 billion at the end of 2022[25]. - The net assets attributable to shareholders decreased by 3.31% to approximately ¥1.74 billion, down from ¥1.80 billion in 2022[25]. - The basic earnings per share for 2023 was -¥0.101, slightly improved from -¥0.107 in 2022[26]. - The weighted average return on equity was -4.06%, an increase of 0.19 percentage points compared to -4.25% in 2022[26]. - Non-recurring gains and losses totaled approximately ¥26.93 million for 2023, compared to ¥20.32 million in 2022[30]. - The company reported a significant increase in government subsidies, amounting to approximately ¥6.23 million in 2023, down from ¥13.59 million in 2022[30]. Audit and Compliance - The report includes a standard unqualified audit opinion from Zhongxing Caiguanghua Accounting Firm[4]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company has maintained its commitment to the accuracy and completeness of the annual report, with all board members present at the meeting[10]. - The report is available for public disclosure through designated media and the Shanghai Stock Exchange website[19]. Market and Industry Insights - The company has described industry risks and potential challenges in its future development discussions[9]. - The report emphasizes the importance of investment risk awareness for investors regarding forward-looking statements[6]. - The pharmaceutical manufacturing industry in China saw a revenue of CNY 25,205.7 billion in 2023, a year-on-year decline of 3.7%[50]. - The chemical pharmaceutical sector is crucial for clinical treatment and has new growth opportunities driven by the increasing demand for new drug development, particularly in oncology and cardiovascular diseases[51]. - The non-surgical medical beauty market is expanding, with the total volume growth of non-surgical treatments surpassing the overall medical beauty market[52]. - The market for hyaluronic acid-based skin fillers in China was valued at CNY 6.4 billion in 2021, with a compound annual growth rate (CAGR) of 19.7% from 2017 to 2021, and is projected to reach CNY 19.6 billion by 2026, with a CAGR of 25.0%[54]. - The market for PLA-based regenerative medical fillers in mainland China reached CNY 1.45 billion in 2022, with a staggering CAGR of 259.4% from 2021 to 2022, and is expected to grow to CNY 11.52 billion by 2027, with a CAGR of 31.2% from 2025 to 2027[55]. Research and Development - The company established a comprehensive R&D management system, launching 8 generic drug projects, including 5 formulations and 3 active pharmaceutical ingredients[38]. - The company is actively developing a recombinant collagen research platform, leveraging AI-driven protein design technology to shorten development cycles[46]. - The company signed a cooperation agreement with Nanjing Dongwan Biotechnology Co., obtaining exclusive rights for recombinant human collagen in specific fields[46]. - The company signed a strategic cooperation framework agreement with Shanghai Oriental Beauty Valley to establish the "Wuzhong Aesthetic Collagen Innovation Bio-Manufacturing Center" in the biopharmaceutical industrial park[47]. - The company has built a highly experienced and efficient R&D, production, and sales team, with over 100 employees across its subsidiaries, primarily sourced from top medical beauty enterprises[48]. - The company is focusing on high-end generic drugs, first-generic drugs, and specialty medications, while also advancing the consistency evaluation of injection and tablet forms[74]. - The company is conducting pharmaceutical research on several new products, including WZ034, WZ035, and WZ045, targeting chronic liver disease, atopic dermatitis, and chronic kidney disease associated with type 2 diabetes[120]. - The company is actively pursuing the development of generic drugs, with multiple products undergoing pharmaceutical research and evaluation[120]. Strategic Initiatives - The company is committed to a dual-driven development strategy focusing on both industrial development and capital operations to enhance market competitiveness[143]. - The company aims to enhance its core competitiveness by integrating pharmaceutical and medical beauty sectors, aiming to form a robust health industry cluster[143]. - The company is focusing on sustainability initiatives, aiming to reduce operational carbon emissions by 30% over the next five years[171]. - The company plans to enhance its market presence in Southeast Asia, targeting a 20% market share within three years[171]. - The company is considering the liquidation of the Nanchang Suwu Health Industry Management Center (Limited Partnership)[180]. Governance and Management - The company held one shareholders' meeting during the reporting period, with all proposals approved, ensuring compliance with legal requirements[163]. - The board of directors conducted four meetings during the reporting period, with all resolutions passed, demonstrating effective governance[164]. - The supervisory board held three meetings, ensuring oversight of the company's financial and operational activities[164]. - The company published four regular reports and 75 temporary announcements, maintaining transparency and timely information disclosure[165]. - The company has developed an investor relations management system to enhance communication with investors and address their concerns[165]. - The total remuneration for directors and senior management during the reporting period amounted to 708.65 million yuan, with the highest individual remuneration being 128.40 million yuan for the chairman and president[168]. - The company has not faced significant changes in competition or business operations from its controlling shareholders, ensuring its operational independence[166]. - The company has proposed a three-year shareholder return plan for 2023-2025, emphasizing its commitment to shareholder value[166]. Human Resources - The company employed a total of 1,050 staff, with 48 in the parent company and 1,002 in major subsidiaries[187]. - The workforce includes 339 production personnel, 251 sales personnel, 197 technical personnel, 39 financial personnel, and 224 administrative personnel[188]. - A comprehensive training program has been initiated, focusing on talent development and management skills across various employee levels[190]. - The company has launched the "Tree People Plan" for management talent development, targeting different management levels[191]. Risk Management - The company faces risks of rising production factor costs due to stricter national standards and environmental regulations, which may lead to increased raw material costs and supply shortages[158]. - The company is focused on lean production to enhance efficiency in response to rising production and operational costs[158]. - The company has a liquidity risk due to a heavy reliance on short-term liabilities, which could impact its short-term debt repayment ability if the financial environment changes[160]. - The company is committed to improving its financial risk management by establishing a robust financial risk identification system[160]. - The company has established a comprehensive emergency management system to mitigate the impact of natural disasters on its operations[159].

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-024 江苏吴中医药发展股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 7 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 125,550,501 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 17.72％ | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，会议由董事长钱群山先生主持。会议采用 现场投票和网络投票相结合的表决方式进行表决。会议的召开和表决程序符合 《公司法》及《公司章程》的规定，会议合法有效。 (一) 股东大会召开的时间：2024 年 3 月 22 日 (二) 股东大会召开的地点：江苏省苏州市吴中区东方大道 988 号，公司会议室。 ( ...